title: The potential epidemiological impact of a genital herpes vaccine for women.
abstract: BACKGROUND
  In two phase III vaccine trials immunisation of women previously uninfected by herpes simplex virus provided protection against genital herpes disease. In deciding policy, an evaluation of the epidemiological impact of the partial protection provided by the vaccine should be considered.
  
  
  METHODS
  A sex and sexual activity stratified deterministic differential and partial differential equation model of the natural history of herpes simplex virus type 2 (HSV-2) and the impact of vaccination is developed and analysed. To explore the role of vaccination, the pattern of viral shedding and the transmission of infection during sexual acts within sexual partnerships are described.
  
  
  RESULTS
  Using literature derived estimates of parameter values and assuming efficacy in only 40% of women the impact of the vaccine depends on assumptions made about its action. The vaccine has a limited impact if it only prevents disease but a more substantial impact if it reduces asymptomatic viral shedding, which it could do indirectly by preventing infection or directly by modifying the biology of the infection. Concern over the implications of a vaccine that prevents disease but has no impact on viral shedding was addressed in a worst case scenario. Here there is a modest increase in the incidence of infection in both men and women but an increase in disease prevalence in men alone, since the virus directly protects some women from disease.
  
  
  CONCLUSIONS
  Results suggest that a herpes vaccine should be used universally and that a vaccine that only protects HSV-1-/2- women can paradoxically have a significant epidemiological impact, the scale of which depends upon changes in patterns of viral shedding.
authors.affiliation: Department of Infectious Disease Epidemiology, Imperial College of Science, Technology and Medicine, St Mary's Campus, Norfolk Place, London, UK. g.garnett@ic.ac.uk
authors.forename: G P
authors.initials: GP
authors.lastname: Garnett
authors.forename: G
authors.initials: G
authors.lastname: Dubin
authors.forename: M
authors.initials: M
authors.lastname: Slaoui
authors.forename: T
authors.initials: T
authors.lastname: Darcis
mesh_terms: D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006558:Herpes Genitalis / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D022301:Herpes Simplex Virus Vaccines; D018258:Herpesvirus 2, Human; D006801:Humans; D008954:Models, Biological; D012307:Risk Factors; D012725:Sexual Behavior; D012747:Sexual Partners; D014611:Vaccination; D017201:Virus Shedding
chemical_list: D022301:Herpes Simplex Virus Vaccines